uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
23.02
-1.35 (-5.54%)
At close: Jan 28, 2026, 4:00 PM EST
23.48
+0.46 (2.00%)
After-hours: Jan 28, 2026, 5:07 PM EST
uniQure Revenue
uniQure had revenue of $3.70M in the quarter ending September 30, 2025, with 61.83% growth. This brings the company's revenue in the last twelve months to $15.75M, down -44.90% year-over-year. In the year 2024, uniQure had annual revenue of $27.12M with 71.17% growth.
Revenue (ttm)
$15.75M
Revenue Growth
-44.90%
P/S Ratio
83.75
Revenue / Employee
$75,364
Employees
209
Market Cap
1.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 516.72M | 7,096.84% |
| Dec 31, 2019 | 7.28M | -5.83M | -44.45% |
| Dec 31, 2017 | 13.11M | -11.99M | -47.78% |
| Dec 31, 2016 | 25.10M | 21.05M | 520.14% |
| Dec 31, 2013 | 4.05M | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.76B |
| Novavax | 1.06B |
| Innoviva | 388.52M |
| Pharming Group | 362.27M |
| Tango Therapeutics | 66.50M |
| Relay Therapeutics | 8.36M |
| DBV Technologies | 5.50M |
| AtaiBeckley | 3.02M |
QURE News
- 19 days ago - uniQure Announces Type A Meeting Scheduled with FDA - GlobeNewsWire
- 20 days ago - uniQure: Now What? - Seeking Alpha
- 6 weeks ago - What's Going On With uniQure Stock On Tuesday? - Benzinga
- 7 weeks ago - Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years - PRNewsWire
- 7 weeks ago - Why uniQure Stock Is Trading Lower After FDA Meeting Update - Benzinga
- 7 weeks ago - uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease - GlobeNewsWire
- 2 months ago - Diamond Hill International Strategy Q3 2025 Performance Review - Seeking Alpha
- 2 months ago - uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE - PRNewsWire